MedTech 100 roundup: Industry reaches another high point

The medtech industry is continuing its massive 2021 boom, with the past week marking yet another record in the markets.

MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 27) at 121.05 points, representing a 1.2% rise from the 119.63-point mark set a week before. Following a slight dip earlier this month, the industry continues to tick up to new heights.

Medtech’s performance continues to reflect an overall rebound from the struggles brought on by the COVID-19 pandemic, too. The industry remains well above the marks set around the height of the pandemic, having registered a 31.1% increase from the pre-pandemic high of 92.32 (set on Feb. 19, 2020). Moreover, it remains well ahead of the mid-pandemic low of 62.13 (March 23, 2020) as well, totaling a 94.8% ascent above that point.

The industry’s performance fell in line with the overall markets this past week as the S&P 500 I…

Read more
  • 0

Encision signs supply agreement with J&J’s Auris Health

Encision today announced that it has entered a supply agreement with Johnson & Johnson (NYSE:JNJ) subsidiary Auris Health .

Through the agreement, Auris Health will buy certain Active Electrode Monitoring technology from Encision. Boulder, Colo.-based Encision will receive an upfront payment and a milestone payment upon certain milestones. The company will also receive revenues from proprietary product sales to Auris Health.

“We are happy to be teaming up with Auris to drive new levels of patient safety in robotic surgery. Encision’s Active Electrode Monitoring is a proprietary and differentiating technology that shields patients and practitioners from radiant energy injuries during standard and robotic laparoscopic surgeries. We welcome this next phase to our relationship,” Encision president and CEO Gregory Trudel said in a news release.

Encision’s Active Electrode Monitoring was designed to prevent dangerous stray electrosu…

Read more
  • 0